Skip to main navigation
Skip to search
Skip to main content
WashU Research Profiles Home
Help & FAQ
Link opens in a new tab
Search content at WashU Research Profiles
Home
Profiles
Research units
Research output
Phase I study of eptifibatide in patients with sickle cell anaemia
Sheritha P. Lee
, Kenneth I. Ataga
,
Mohamed Zayed
, Jeanne M. Manganello
, Eugene P. Orringer
, David R. Phillips
, Leslie V. Parise
Roy and Diana Vagelos Division of Biology & Biomedical Sciences (DBBS)
Institute of Clinical and Translational Sciences (ICTS)
Section of Vascular Surgery
DBBS - Molecular Cell Biology
DBBS - Biochemistry, Biophysics, and Structural Biology
DBBS - Cancer Biology
Center of Regenerative Medicine
DBBS - Developmental, Regenerative and Stem Cell Biology
Research output
:
Contribution to journal
›
Article
›
peer-review
41
Link opens in a new tab
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Phase I study of eptifibatide in patients with sickle cell anaemia'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Phase I Study
100%
Sickle Cell Anemia
100%
Eptifibatide
100%
Acute Coronary Syndrome
37%
CD40 Ligand (CD40L)
25%
Plasma Parameters
25%
Platelet Aggregation
25%
Tumor Necrosis Factor-α
12%
Pathophysiology
12%
Effective Treatment
12%
Inflammatory Mediators
12%
Inflammation
12%
Steady State
12%
Vasodilation
12%
Macrophage Inflammatory Protein 1α
12%
Biochemical Parameters
12%
Pharmacodynamics
12%
P-selectin
12%
Matrix metalloproteinase-9 (MMP-9)
12%
Leptin
12%
Myoglobin
12%
Platelet Inhibition
12%
Platelet-leukocyte Aggregates
12%
Coagulation Parameters
12%
Ligand Release
12%
Matrix metalloproteinase-2 (MMP-2)
12%
Soluble CD40L
12%
Aggregate Formation
12%
Platelet Reactivity
12%
Platelet Factor 4
12%
Soluble CD40 Ligand
12%
Hematological Parameters
12%
β-thromboglobulin
12%
Medicine and Dentistry
Sickle-Cell Disease
100%
Eptifibatide
100%
CD40 Ligand
50%
Thrombocyte Aggregation
37%
Acute Coronary Syndrome
37%
Infusion
25%
Leukocyte
12%
Platelet
12%
Pathophysiology
12%
Steady State
12%
Vasodilatation
12%
Pharmacodynamics
12%
PADGEM Protein
12%
Matrix Metalloproteinase
12%
Gelatinase B
12%
Inflammatory Mediator
12%
Leptin
12%
Myoglobin
12%
Tumor Necrosis
12%
Gelatinase A
12%
Macrophage Inflammatory Protein 1
12%
Platelet Reactivity
12%
Thrombocyte Factor 4
12%
Beta Thromboglobulin
12%
Effective Treatment
12%
Pharmacology, Toxicology and Pharmaceutical Science
Sickle Cell Anemia
100%
Eptifibatide
100%
CD40 Ligand
50%
Acute Coronary Syndrome
37%
Pharmacodynamics
12%
Inflammation
12%
Pathophysiology
12%
Macrophage Inflammatory Protein 1
12%
Leptin
12%
Matrix Metalloproteinase
12%
Gelatinase B
12%
Thrombocyte Factor 4
12%
Gelatinase A
12%
Myoglobin
12%
Tumor Necrosis
12%
P-Selectin
12%
Beta Thromboglobulin
12%
Biochemistry, Genetics and Molecular Biology
Eptifibatide
100%
Thrombocyte Aggregation
37%
Blood Level
25%
Leukocyte
12%
Mediator
12%
Synapsin I
12%
Steady State
12%
Matrix Metalloproteinase
12%
Vasodilatation
12%
Pharmacodynamics
12%
Gelatinase B
12%
MMP9
12%
Tumor Necrosis Factor Alpha
12%
Gelatinase A
12%
MMP2
12%
Macrophage Inflammatory Protein
12%
Platelet Reactivity
12%
Platelet Factor 4
12%
P-Selectin
12%
Beta-Thromboglobulin
12%
Leptin
12%
Platelet
12%
Myoglobin
12%